

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Wilkinson Peter J</u>  (Last) (First) (Middle) 231 MAPLE AVENUE  (Street) BURLINGTON NC 27215  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>LABORATORY CORP OF AMERICA HOLDINGS [ LH ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director _____ 10% Owner _____ Officer (give title below) _____ Other (specify below) _____ SVP, Chief Accounting Officer
	3. Date of Earliest Transaction (Month/Day/Year) 02/12/2021	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	02/12/2021		M		187	A	(1)	710.2194	D	
Common Stock	02/12/2021		F(2)		62	D	\$238.26	648.2194	D	
Common Stock	02/12/2021		M		680	A	(1)	1,328.2194	D	
Common Stock	02/12/2021		F(2)		201	D	\$238.26	1,127.2194	D	
Common Stock	02/18/2021		M		1,533	A	\$146.59	2,660.2194	D	
Common Stock	02/18/2021		S		2,317	D	\$241.5146(3)	343.2194	D	
Common Stock	02/18/2021		M		633	A	\$182.51	976.2194	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Restricted Stock Unit	(1)	02/12/2021		M			187	(4)	(4)	Common Stock	187	\$0	2,347(5)	D	
Restricted Stock Unit	(1)	02/12/2021		M			680	(4)	(4)	Common Stock	680	\$0	1,667(5)	D	
Non-qualified Stock Options(6)	\$146.59	02/18/2021		M			1,533	02/12/2020(7)	02/11/2029	Common Stock	1,533	\$0	767	D	
Non-qualified Stock Options(6)	\$182.51	02/18/2021		M			633	02/04/2021(7)	02/03/2030	Common Stock	633	\$0	1,267	D	

**Explanation of Responses:**

- Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
- Stock withholding to satisfy tax withholding obligations.
- The price of \$241.5146 per share represents a weighted average of sales prices ranging from \$240.92 to \$241.651 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
- The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 12, 2020.
- This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
- Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
- The option vests in three equal annual installments beginning on the date reflected in this column.

/s/ Sandra D. van der Vaart,  
Attorney-in-Fact for Peter J. Wilkinson      02/19/2021

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

